Study of Verinurad in Heart Failure With Preserved Ejection Fraction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.
Also called NCT04327024
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 159 participants
- Sponsor
- Registry
-
NCT04327024 -
2019-004862-16
-
- Other papers using this trial's data
- Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Bulgaria, Canada, Germany, Mexico, Poland, Russia, Slovakia, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04327024. Randomized; triple masking; primary purpose treatment. Start 2020-05-19 (actual); primary completion 2022-04-29 (actual). Results posted on 2023-06-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Verinurad in Heart Failure With Preserved Ejection Fraction
- Acronym
- AMETHYST
- Intervention (Drug)
- Verinurad
- Intervention (Drug)
- Allopurinol
- Intervention (Drug)
- Placebo for verinurad
- Intervention (Drug)
- Placebo for allopurinol
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct04327024- Content hash
d72023ef5ba73bf245057afac0f3416684e5d25221841dcb20ae82b70b3db6ee